济南射精快不受控制怎么办(济南尿道有点刺痛) (今日更新中)

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

With election day looming, the candidates vying to replace Duncan Hunter in East County's 50th Congressional District say they are leaving no stone uncovered.The race is pitting Republican Darrell Issa against Democrat Ammar Campa-Najjar. The two want to fill the seat Hunter vacated in January, when he resigned after pleading guilty to one felony campaign fraud charge. Campa-Najjar narrowly lost to a then-indicted Hunter in 2018 and is running again in 2020."The whole district, we're just going to be traveling across town, meeting people at local diners and saying 'hey, I'm here for you,'" Campa-Najjar said Monday. Issa represented coastal North County's 49th for nearly two decades. In 2018, he decided not to run for re-election as that district shifted blue. This year, however, Issa launched a campaign for the seat in the 50th after Hunter resigned. The district comprises much of East County, and stretches into south Riverside County. It is the only district in San Diego County in which Republicans outnumber Democrats. Issa said his campaign made 10,000 calls Sunday and knocked on more than 1,500 doors. He said if he is elected to Congress, he'd use his experience to help move the country forward. "Many of my Republican and Democratic friends are coming back after two years of very little progress and a lot of hostility," he said. "I'm hoping to get past that with people I have a working relationship with and get some things done."After months of polling showing the two neck-and-neck, an Oct. 27 ABC-10 Union-Tribune poll showed Issa with an 11 point lead over Campa-Najjar. Thad Kousser, a political scientist at UC San Diego, said, however, that Tuesday's early results could show Campa-Najjar starting in the lead due to increasingly Democratic early voting."Things are going to look good for Ammar Campa-Najjar by 8:05, 8:15, the next set of returns that come in are going to be the ones between 9 and 10:30 that will come from polling places," he said. noting that could be as much as a 10 or 15 point swing for Issa, until the rest of the balance come in. 2096

With more than 5 million COVID-19 cases in the United States, the one group that has seen a noticeable rise in infections is children.Over the past four weeks, there has been a 90% spike in known COVID-19 cases among children in the U.S., according to the American Academy of Pediatrics and the Children's Hospital Association."While children represented only 9.1% of all cases in states reporting cases by age, over 380,000 children have tested positive for COVID-19 since the onset of the pandemic," the association wrote in a report. Although, we're seeing more American kids being diagnosed with COVID-19, the mortality rate remains relatively low compared to adults. The association says children represented 0% to 0.4% of all COVID-19 deaths, and 19 states reported zero child deaths. In states reporting, 0% to 0.5% of all child COVID-19 cases resulted in death.Public health officials have warned about opening schools in states with COVID-19 hot-spots. Medical experts say having youth in crowded hallways and classrooms poses a significant threat.There are currently 800 students in Georgia's Cherokee County that are in quarantine due to possible coronavirus exposure. This is just one week after in-person learning began.Some health experts like Michael Osterholm, a director at the Center for Infectious Disease Research and Policy, are concerned another big spike in cases is on the way."We think we're going to see an explosion of cases in September that will far surpass what we saw after Memorial Day and this is just going to continue increasing, getting higher and higher in terms of numbers," said Osterholm.Researchers say an effective testing strategy would help communities properly determine if and when to reopen schools for in-person teaching.This story was originally published by Julia Varnier at WTKR. 1838

When it comes to our cars, the cost of gas, oil changes, tires, insurance, and those dreaded repairs all add up. Many drivers don't realize how much their car really costs them.Kat Coughlin knows how expensive an older car can become."The tie rod, the tires, the transmission went out," she said about her older Taurus. "I think we spent about ,000 trying to repair it."Repairs like that can blow the budget. So it helps to know the true cost of owning a car, not just the monthly cost that the salesman puts on the sales sheet.AAA adds up all the costs and feesA new study by AAA finds the average cost of owning a new car is ,469 a year for 2017, when you factor in depreciation, insurance, gas and maintenance costs.AAA says a lot of people buy a car just based on emotions, looking only at that monthly payment of, say, 0 a month. But AAA says you are really paying 0 a month, on average.The agency says drivers don't stop to think what it will cost to maintain the car over a year or two, whether or not it is off the manufacturer's warranty.Bobby Drake is the head mechanic at an AAA repair shop."Even if it's a relatively new car you still have a lot of maintenance," he said.He says many people add to those costs by postponing maintenance, to save a few bucks now.For instance, he sees them wait for the brakes to wear down to metal, and start grinding. That will require costly new rotors in most cases, he says, turning a 0 brake-pad job into a 0 brake and rotor job."Follow the manufacturer's recommended maintenance, and that will definitely save you a lot of money in the long run."Differences between vehicle typesMeantime AAA says some types of vehicles cost a lot more to operate than others.Assuming gasoline at .34 a gallon, AAA says you can expect to pay the following amounts. 1848

While many think of NASA as the government agency that sends scientists into space, some of NASA’s most important work frequently is used to help people on Earth.In recent months, NASA has used its extensive network of scientists and researchers to combat the coronavirus. And in short order, the agency provided patients and healthcare providers with tools that may have been used to save lives.This week, NASA outlined a number of innovations the agency developed to support the fight against the virus.NASA created an open source for N95 respirators so people can make their own masks by using 3D printers. N95 respirators are unique as they protect the wearer from the virus. NASA’s designs were engineered to meet or exceed standard N95 performance, can be used for different purposes, are compatible with commercially-available filters, and do not disrupt the supply chain.If you have access to a 3D printer, here is how to create an N95 respirator designed by NASA.In addition to NASA’s open-source N95 respirators, the team from Johnson Space Center developed and tested a sterilization protocol to combat a national shortage of N95 masks. This allows N95 respirators to be reused by healthcare providers.“I had a very deep and personal connection to the evaluation (of N95 masks), because my wife is a medical professional… on the frontlines, with only one mask allocated for her to use and re-use daily,” said NASA engineer and project lead Jeremy Jacobs. “She has been very concerned about cross contamination between patient-to-patient and to our family.”Among other innovations, NASA’s Jet Propulsion Laboratory in California designed a new high-pressure ventilator tailored specifically to treat COVID-19 patients. It was designed to treat patients who might not require a full-featured ventilator, keeping the nation’s limited supply of traditional ventilators available, NASA said.NASA’s Armstrong Flight Research Center in California joined several other agencies to create a helmet that functions like a continuous positive airway pressure, commonly known as CPAP, machine to force oxygen into a patient’s low-functioning lungs. 2156

来源：资阳报